CLIMB^TM

 

CLIMB^TM is SuperGen’s approach to small molecule drug discovery, which merges rapid screening of compound libraries with computational chemistry and systems biology techniques to identify drug leads that bind to target proteins.

 

CLIMB^TM is an iterative and evolving process, incorporating techniques from computational design to laboratory bench biology and chemistry, to yield targeted therapeutics for use in the clinic. In traditional small molecule screening, as many as several million compounds may be tested in order to identify the few that interact selectively with a disease-related protein target. 

 

CLIMB^TM has been used to achieve superior results by screening as few as several hundred rationally-selected compounds, all of which exhibit considerable activity. This reduces the time from target identification to clinical candidate by several years, and vastly decreases the cost of drug development. As part of CLIMB™ our talented software development team is actively involved in the creation of algorithms to integrate computation, biochemistry, medicinal chemistry and systems biology, streamlining the drug discovery process even further.

 

The CLIMB™ process:

• Cluster large libraries into representative pharmacophore “primary screening set”
• Dock primary screening set into in silico model of protein target
  • Iterative secondary and tertiary screens to elucidate a set of candidates
• Highest ranking 3000-5000 compounds based on docking subjected to predictive ADME filtering
• Top 200-300 compounds purchased or synthesized for use in biochemical screening to determine lead
  • Compare to several hundred thousand compounds screened in traditional drug discovery approaches, to identify few leads
• Intellectual property and literature search to evaluate IP landscape around lead
• Traditional synthetic and medicinal chemistry to develop leads into drug candidates